Lamotrigine Tablet
NDC Package 42291-367-01
Package Information
Lamotrigine tablets is lamotrigine is used alone or with other medications to prevent and control seizures. This formulation utilizes a tablet delivery system. Marketed by Avkare, this product is identified by NDC 42291-367 and is authorized under FDA application ANDA079132.
Identification & Billing
- RxCUI: 198427 - lamoTRIgine 100 MG Oral Tablet
- RxCUI: 198427 - lamotrigine 100 MG Oral Tablet
- RxCUI: 198428 - lamoTRIgine 150 MG Oral Tablet
- RxCUI: 198428 - lamotrigine 150 MG Oral Tablet
- RxCUI: 198429 - lamoTRIgine 200 MG Oral Tablet
Clinical Specifications
- Anti-epileptic Agent - [EPC] (Established Pharmacologic Class)
- Decreased Central Nervous System Disorganized Electrical Activity - [PE] (Physiologic Effect)
- Dihydrofolate Reductase Inhibitors - [MoA] (Mechanism of Action)
- Mood Stabilizer - [EPC] (Established Pharmacologic Class)
- Organic Cation Transporter 2 Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 42291 - Avkare
- 42291-367 - Lamotrigine
- 42291-367-01 - 100 TABLET in 1 BOTTLE
- 42291-367 - Lamotrigine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (42291-367). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 42291-367-01 identifies a specific commercial package of 100 tablet in 1 bottle of Lamotrigine, a human prescription drug labeled by Avkare. This product is billed for "EA" each discreet unit and contains an estimated amount of 100 billable units per package. This tablet is formulated for oral use and contains lamotrigine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Avkare on April 10, 2013. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).
How is this Avkare product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 42291036701. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.